Academic Journal
Synthesis, Characterization, and In Vitro and In Silico Studies of New Triazole Derivatives as Aromatase Inhibitors.
| Τίτλος: | Synthesis, Characterization, and In Vitro and In Silico Studies of New Triazole Derivatives as Aromatase Inhibitors. |
|---|---|
| Συγγραφείς: | Uzmez ZL; Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey., Osmaniye D; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey.; Central Analysis Laboratory, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey., Ozkay Y; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey.; Central Analysis Laboratory, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey., Kaplancıklı ZA; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey. |
| Πηγή: | Medicinal chemistry (Shariqah (United Arab Emirates)) [Med Chem] 2025; Vol. 21 (4), pp. 309-318. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Bentham Science Publishers Country of Publication: Netherlands NLM ID: 101240303 Publication Model: Print Cited Medium: Internet ISSN: 1875-6638 (Electronic) Linking ISSN: 15734064 NLM ISO Abbreviation: Med Chem Subsets: MEDLINE |
| Imprint Name(s): | Publication: Amsterdam : Bentham Science Publishers Original Publication: Sharjah, U.A.E.; San Francisco, CA : Bentham Science Publishers |
| Ιατρικοί όροι (MeSH): | Aromatase Inhibitors*/pharmacology , Aromatase Inhibitors*/chemical synthesis , Aromatase Inhibitors*/chemistry , Triazoles*/pharmacology , Triazoles*/chemical synthesis , Triazoles*/chemistry , Antineoplastic Agents*/chemical synthesis , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry, Aromatase/metabolism ; Cell Proliferation/drug effects ; Humans ; Structure-Activity Relationship ; Molecular Docking Simulation ; Drug Screening Assays, Antitumor ; MCF-7 Cells ; Molecular Structure ; A549 Cells ; Dose-Response Relationship, Drug |
| Περίληψη: | Introduction: Breast cancer is the most common type of cancer among women. Steroidal or non-steroidal aromatase inhibitors (NSAIs) are used clinically, and in most cancer diseases, resistance is the most important problem. Methods: The nitrogenous heterocyclic ring is noteworthy in the structure of non-steroidal aromatase inhibitors. This is the pharmacophore structure for aromatase inhibition. Because the enzyme interacts with the Fe2+ cation of the HEM structure in its active site, the most used agents in the clinic, such as anastrozole and letrozole, contain triazoles in their structures. Within the scope of this study, hybrid compounds containing both imidazole and triazole were synthesized. Results: The synthesis was carried out by a 4-step reaction. The anticancer effects of the compounds were evaluated by MTT assay performed on A549 and MCF-7 cancer cells. Compound 4d showed anticancer activity against the MCF-7 cell line with IC Conclusion: The interactions observed as a result of molecular docking and dynamics studies are in harmony with activity studies. In particular, interactions with HEM600 demonstrate the activity potential of the compound. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.) |
| References: | Bioorg Chem. 2019 Dec;93:103327. (PMID: 31614285) Eur J Med Chem. 2011 Sep;46(9):4010-24. (PMID: 21703734) Molecules. 2021 Jul 02;26(13):. (PMID: 34279404) Eur J Med Chem. 2022 Oct 5;240:114569. (PMID: 35834906) Eur J Med Chem. 2021 Jan 15;210:112979. (PMID: 33183865) Eur J Med Chem. 2022 Dec 15;244:114802. (PMID: 36240547) Eur J Med Chem. 2021 Dec 15;226:113837. (PMID: 34530384) Biotechnol Annu Rev. 2005;11:127-52. (PMID: 16216776) Nature. 2009 Jan 8;457(7226):219-23. (PMID: 19129847) Bioorg Med Chem. 2015 Jul 1;23(13):3472-80. (PMID: 25934226) J Biomol Struct Dyn. 2022 Oct;40(17):7991-8003. (PMID: 33970806) Eur J Med Chem. 2020 Jan 1;185:111815. (PMID: 31732252) CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. (PMID: 24399786) ChemMedChem. 2008 Nov;3(11):1708-30. (PMID: 18816537) ChemMedChem. 2013 May;8(5):779-99. (PMID: 23495205) Eur J Med Chem. 2021 Nov 15;224:113733. (PMID: 34364162) Bioorg Chem. 2022 May;122:105709. (PMID: 35255344) Bioorg Med Chem. 2016 Oct 1;24(19):4723-4730. (PMID: 27567077) Int J Mol Sci. 2021 Oct 02;22(19):. (PMID: 34639036) J Chem Theory Comput. 2017 Apr 11;13(4):1518-1524. (PMID: 28267328) Eur J Med Chem. 2021 Feb 5;211:113115. (PMID: 33360796) Eur J Med Chem. 2013 Nov;69:99-114. (PMID: 24012714) Eur J Med Chem. 2021 Nov 15;224:113737. (PMID: 34365129) Spectrochim Acta A Mol Biomol Spectrosc. 2022 Nov 5;280:121530. (PMID: 35752037) |
| Grant Information: | 1919B012201803 Research Fund of Tubitak 2209-A project |
| Contributed Indexing: | Keywords: Breast cancer; aromatase inhibitor; estrogen.; molecular docking; molecular dynamics; triazole |
| Substance Nomenclature: | 0 (Aromatase Inhibitors) 0 (Triazoles) 0 (Antineoplastic Agents) EC 1.14.14.1 (Aromatase) |
| Entry Date(s): | Date Created: 20250512 Date Completed: 20250512 Latest Revision: 20251114 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12606616 |
| DOI: | 10.2174/0115734064316112240722092935 |
| PMID: | 40351069 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!